China's Zixin Pharmaceutical buys majority stake in U.S. genome firm Nabsys

Two scientists in a lab

China’s Jilin Zixin Pharmaceutical Industrial has splashed out $42 million to buy a Rhode Island-based high-definition genome mapping company, Nabsys 2.0, entering an area fairly outside of its traditional Chinese medicine base.

China Money Network reports that Zixin will hold 67% of Nabsys, which, according to its website, underwent a financial, management and technical leadership team restructuring in March.

Chinese pharmaceutical and contract research firms have made several forays into areas of genome mapping, offering services in the field to other companies or in other cases for drug discovery research.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Zixin's aim for the stake was not immediately clear, though it has partnered Chinese gene sequence firm BGI on earlier work and has an in-house R&D effort that includes cardiovascular and cerebrovascular components aimed at the domestic market.

Nabsys says its chip-based nanodetectors can analyze complex DNA molecules electronically at high velocity and deep resolution compared to optical approaches, according to the company's website.

The transaction values Nabsys at $63 million, according to China Money Network.

- here's the release (Chinese language)
- and a story from China Money Network

Related Articles:
China poised to make CRISPR history with first in-vivo trial
China's BGI and Huawei partner on Big Data genomic system storage


Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.

Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.